IGHE and allergic disease: Low-dose oral immunotherapy (OIT) protocols have attracted increasing attention due to their improved safety profile, with a reduced incidence of IgE-mediated allergic reactions and treatment-emergent adverse events (TEAEs) [10,16,17,18,19].